-
The average price of artificial joints has been reduced by more than 80%, and enterprises are expected to achieve "price-for-volume"
Time of Update: 2022-04-15
The "Selected Results of Centralized Procurement of Artificial Joints by the State Organization" included in the "Notice" shows that the hip joint products in this centralized procurement are divided into three groups according to ceramic-ceramic, ceramic-polyethylene, and alloy-polyethylene.
-
New progress in the consistency evaluation of generic drugs! Last week, 5 pharmaceutical companies were the first to review
Time of Update: 2022-04-15
According to incomplete statistics, in the last week (March 20, 2022-March 26, 2022), 23 new varieties (deemed as) have been reviewed, of which 5 are the first review, namely Hengrui's gadolinium Butol injection, Hisco's arginine and glutamate injection, Chia Tai Tianqing's methacholine for inhalation, Heyi Pharmaceutical's lidocaine hydrochloride ophthalmic gel, Chengji Pharmaceutical's cyproheptadine hydrochloride Oral solution .
-
The gospel of over 15 million atrial fibrillation patients!
Time of Update: 2022-04-15
Recently, there is good news that Sanofi's new anti-arrhythmic drug, Midarone Dronedarone Hydrochloride Tablets, has been launched in China for sinus rhythm patients with a history of paroxysmal or persistent atrial fibrillation (AF).
-
One million yuan a shot of CAR-T cell therapy products, or fight for medical insurance!
Time of Update: 2022-04-15
In addition, Fosun Pharma stated that the technology transfer of the second CAR-T product has been completed within the reporting period, and the clinical trial application for relapsed or refractory mantle cell lymphoma was approved for clinical trials by the State Food and Drug Administration in March 2022.
-
This week, a group of pharmaceutical companies have "changed coaches" one after another
Time of Update: 2022-04-15
On March 31, Keixing Pharmaceutical announced the appointment of Wu Kun as Chief Commercial Officer .
On March 29, Hainan Haiyao issued an announcement showing that the board of directors received a written resignation application report from the chairman of the company, Mr.
-
The use of artificial intelligence to develop new treatments has become a trend in the industry
Time of Update: 2022-04-15
[Pharmaceutical Network Industry News] With the rise of a new generation of information technology and the development of many high-tech fields, a series of cutting-edge technologies represented by artificial intelligence have begun to shine in various traditional fields.
-
Clinical trials of multiple drugs have made new progress!
Time of Update: 2022-04-15
Sino Biopharma recently announced that the Group's self-developed Class I anti-tumor innovative drug "FHND5071" has been approved for clinical trials for the treatment of advanced solid tumors .
-
The 15th "World Autism Day", the current situation of drug research and development attracts attention
Time of Update: 2022-04-15
In the United States, the current drugs for autism treatment, risperidone and aripiprazole, are antipsychotic drugs, not for core symptoms .
In 2006, the FDA approved Johnson & Johnson's risperidone for the treatment of irritability in children with autism from 5 to 16 years old.
-
Since March, a number of pharmaceutical equipment companies have received the attention of securities companies' research reports
Time of Update: 2022-04-15
Since March, a number of pharmaceutical equipment companies have received the attention of research reports from securities companies, including Chutian Technology, Tofflon, and Chengyitong .
-
Another domestic HPV vaccine is about to be approved!
Time of Update: 2022-04-15
[Pharmaceutical Network Industry News] Recently, the website of the Food and Drug Administration showed that the marketing application of the recombinant human papillomavirus bivalent (16/18 type) vaccine (yeast) of a subsidiary of Watson Bio (acceptance numbers: CXSS2000024, CXSS2000025, pre-filled The two dosage forms of syringe and vial) have entered the stage of "administrative approval" and are expected to be launched soon .
-
The outbreak of anti-tumor drugs is imminent, and many pharmaceutical companies have several varieties under development
Time of Update: 2022-04-15
In the face of a considerable market blue ocean, in recent years, a large number of domestic and foreign pharmaceutical companies have been attacking the anti-tumor drug market, increasing investment in research and development, strengthening cooperation between companies, and enriching the company's product pipeline .
-
Another batch of pharmaceutical companies, layoffs!
Time of Update: 2022-04-15
Recently, another batch of pharmaceutical companies made layoff decisions: Biogen announced layoff-related matters to some employees in the United States; Dongpei Pharmaceuticals basically disbanded its sales team in China; Gilead plans to lay off 114 employees in Morris Plains, New Jersey.
-
With the continuous emergence of innovative achievements, pharmaceutical companies' innovative drug revenue growth rate is strong
Time of Update: 2022-04-15
It is worth mentioning that in the context of the continuous launch of innovative drugs, the growth rate of a large number of drug revenues is also very strong, which has brought benefits to many pharmaceutical companies .
-
4 more injection varieties passed the consistency evaluation!
Time of Update: 2022-04-15
[Pharmaceutical Network Industry News] Recently, on March 24, 2022, the drug approval certificate pending information release, a total of 17 varieties have passed/deemed to pass the consistency of generic drugs, of which 4 varieties are injections/injectable drugs, including injection Cefoperazone Sodium Sulbactam Sodium (Lijian Pharmaceutical), Arginine Glutamate Injection (Haisco), Cefepime Hydrochloride for Injection (Xinfeng Pharmaceutical), Gadobutrol Injection (Hengrui Pharmaceutical), and There are 2 varieties that have been reviewed by the head home .
-
good news!
Time of Update: 2022-04-15
[Pharmaceutical Network Industry News] Recently, Hainan Boao Lecheng International Medical Tourism Pilot Zone has successfully introduced the invasive fungal disease treatment drug-AmBisome (Amphotericin B liposome for injection), which will provide domestic invasive fungal diseases.
-
2022 first quarter performance forecasts have been disclosed one after another, a pharmaceutical company’s revenue and net profit have both surged
Time of Update: 2022-04-15
Kelun Pharmaceutical expects that in the first quarter of 2022, the year-on-year growth rate of net profit attributable to the parent will rebound to 32%, 50%-70%, and the generic drug business will usher in a cash-out period .
-
Over 300 companies have received institutional attention!
Time of Update: 2022-04-15
Institutions mainly focus on the company's views on DRG/DIP, the current competitive landscape of developing countries, how the company can ensure the long-term growth of developing countries in the future, and the progress of medical treatment in overseas markets .
-
A large number of pharmaceutical companies continued to perform well in the first quarter, with a sharp increase in net profit
Time of Update: 2022-04-15
Kelun Pharmaceutical expects that in the first quarter of 2022, the year-on-year growth rate of net profit attributable to the parent will rebound to 32%, 50%-70%, and the generic drug business will usher in a cash-out period .
-
In the past 5 days, this pharmaceutical stock has been investigated by more than 60 institutions, with a net inflow of over 100 million
Time of Update: 2022-04-15
In the communication and interaction session, the agency mainly focused on the company's business development, the reasons for the increase in performance, the number of orders in hand, the impact of traditional Chinese medicine policies on the company's business, the current situation of Shaoxing's CDMO and future plans .
-
A large number of domestic pharmaceutical companies are speeding up to grab the market for original research drugs!
Time of Update: 2022-04-15
It is worth mentioning that, in addition to Nanjing Chia Tai Tianqing, there are more than 10 domestic pharmaceutical companies that have obtained clinical approval for ramelteon tablets.
